IMPDH2 promotes cell proliferation and epithelial‑mesenchymal transition of non‑small cell lung cancer by activating the Wnt/&beta;‑catenin signaling pathway

Xu,Hao; Ma,Hongda; Zha,Lifen; Li,Qian; Yang,Guanghui; Pan,Huiming; Fei,Xiangping; Xu,Xingxiang; Xing,Chen; Zhang,Ladi

doi:10.3892/ol.2020.12082

IMPDH2 promotes cell proliferation and epithelial‑mesenchymal transition of non‑small cell lung cancer by activating the Wnt/β‑catenin signaling pathway

Authors:
- Hao Xu
- Hongda Ma
- Lifen Zha
- Qian Li
- Guanghui Yang
- Huiming Pan
- Xiangping Fei
- Xingxiang Xu
- Chen Xing
- Ladi Zhang
View Affiliations

Affiliations: Department of Respiratory, The People's Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Danyang, Jiangsu 212300, P.R. China
Published online on: September 9, 2020 https://doi.org/10.3892/ol.2020.12082
Article Number: 219

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inosine 5'‑monophosphate dehydrogenase type II (IMPDH2) is an important enzyme involved in the biosynthesis of guanine nucleotides. Therefore, the present study aimed to investigate the potential and molecular mechanism of IMPDH2 in non‑small cell lung cancer (NSCLC). Reverse transcription‑quantitative PCR and immunohistochemistry were used to detect IMPDH2 expression levels in NSCLC tissues and cells. A Cell Counting Kit‑8 assay, colony formation assay, flow cytometry, wound healing, Transwell assay, western blotting and immunofluorescence analyses were utilized to identify the effects of upregulated IMPDH2 levels on NSCLC cells. The expression levels of IMPDH2 have been discovered to be upregulated in several types of human cancer; however, the biological and clinical value of IMPDH2 in NSCLC remains unclear. The results of the present study revealed that the expression levels of IMPDH2 were significantly upregulated in NSCLC tissues. Furthermore, the genetic knockdown of IMPDH2 significantly hindered the proliferation, apoptosis, invasion, migration and epithelial‑mesenchymal transition of NSCLC cells, whereas the overexpression of IMPDH2 achieved the opposite results. In addition, the results of the present study demonstrated that the inhibition of IMPDH2 inhibited the Wnt/β‑catenin signaling pathway by decreasing the expression levels of Wnt3a and β‑catenin, while increasing the expression levels of phosphorylated glycogen synthase kinase‑3β in NSCLC cells. These findings of the present study indicated that IMPDH2 may promote NSCLC progression by activating the Wnt/β‑catenin signaling pathway, which suggested that IMPDH2 may be a novel therapeutic target for patients with NSCLC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Liu R, Chen Y, Shou T, Hu J and Qing C: miRNA-99b-5p targets FZD8 to inhibit non-small cell lung cancer proliferation, migration and invasion. Onco Targets Ther. 12:2615–2621. 2019. View Article : Google Scholar : PubMed/NCBI
3	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
4	Zimmermann AG, Spychala J and Mitchell BS: Characterization of the human inosine-5-momophosphate dehydrogenase type II gene. J Biol Chem. 270:6808–6814. 1995. View Article : Google Scholar : PubMed/NCBI
5	Dorn AR, Mountain LD, Ghoshal M, Hui RA, Klinedinst LK, Rugaber JE, Schamerloh AF and Salamone SJ: The use of inosine 5′-monophosphate dehydrogenase (IMPDH) in the development of a new liquid homogeneous enzyme immunoassay technology. Clin Chem. 47:1921–1922. 2001. View Article : Google Scholar
6	Carr SF, Papp E, Wu JC and Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 266:27286–27290. 1993.
7	Colby TD, Vanderveen K, Strickler MD, Markham GD and Goldstein BM: Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design. Proc Natl Acad Sci USA. 96:3531–3536. 1999. View Article : Google Scholar : PubMed/NCBI
8	Duan S, Huang W, Liu X, Liu X, Chen N, Xu Q, Hu Y, Song W and Zhou J: IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways. J Exp Clin Canc Res. 37:3042018. View Article : Google Scholar
9	Zhou L, Xia D, Zhu J, Chen Y, Chen G, Mo R, Zeng Y, Dai Q, He H, Liang Y, et al: Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer. Clin Transl Oncol. 16:906–913. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zou J, Han Z, Zhou L, Cai C, Luo H, Huang Y, Liang Y, He H, Jiang F, Wang C and Zhong W: Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer. Med Oncol. 32:3732015. View Article : Google Scholar : PubMed/NCBI
11	Kahlert UD, Nikkhah G and Maciaczyk J: Epithelial-tomesenchymal(−like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 331:131–138. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhang X, Ke X, Pu Q, Yuan Y, Yang W, Luo X, Jiang Q, Hu X, Gong YI and Tang K: MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway. Oncotarget. 7:14569–14585. 2016. View Article : Google Scholar : PubMed/NCBI
13	Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methods. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Gao C, Yao H, Liu H, Feng Y and Yang Z: TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer. BMC Cancer. 19:2372019. View Article : Google Scholar : PubMed/NCBI
16	Kozhevnikova EN, van der Knaap JA, Pindyurin AV, Ozgur Z, van Ijcken WF, Moshkin YM and Verrijzer CP: Metabolic enzyme IMPDH is also a transcription factor regulated by cellular state. Mol Cell. 47:133–139. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bairagya HR, Mukhopadhyay BP and Bera AK: Role of salt bridge dynamics in inter domain recognition of human IMPDH isoforms: An insight to inhibitor topology for isoform-II. J Biomol Struct Dyn. 29:441–462. 2011. View Article : Google Scholar : PubMed/NCBI
18	Liu Y, Wang WM, Zou LY, Li LI, Feng LU, Pan MZ, Lv MY, Cao Y, Wang H, Kung HF, et al: Ubiquitin specific peptidase 5 mediates Histidine-rich protein Hpn induced cell apoptosis in hepatocellular carcinoma through P14-P53 signaling. Proteomics. 17:2017. View Article : Google Scholar
19	Jackson RC, Weber G and Morris HP: IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature. 256:331–333. 1975. View Article : Google Scholar : PubMed/NCBI
20	Collart FR, Chubb CB, Mirkin BL and Huberman E: Increased inosine-5-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res. 52:5826–5828. 1992.PubMed/NCBI
21	Nagai M, Natsumeda Y and Weber G: Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res. 52:258–261. 1992.PubMed/NCBI
22	Zhao Y, Yang Y, Dai J, Xing D and Dong Y: IMPDH2 is highly expressed in breast cancer and predicts unfavourable prognosis. Biomarkers. 1–9. Jun 30–2018.(Online ahead of print).
23	Xu Y, Zheng Z, Gao Y, Duan S, Chen C, Rong J, Wang K, Yun M, Weng H, Ye S and Zhang J: High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma. Sci Rep. 7:7452017. View Article : Google Scholar : PubMed/NCBI
24	Zimmermann AG, Wright KL, Ting JP and Mitchell BS: Regulation of inosine-5′-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5 palindromic octamer sequence. J Biol Chem. 272:22913–22923. 1997. View Article : Google Scholar : PubMed/NCBI
25	Wu TY, Peng Y, Pelleymounter LL, Moon I, Eckloff BW, Wieben ED, Yee VC and Weinshilboum RM: Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: Gene sequence variation and functional genomics. Br J Pharmacol. 161:1584–1598. 2010. View Article : Google Scholar : PubMed/NCBI
26	Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Gouill SL, Shiraishi N, Yasui H, Roccaro AM, et al: Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 24:5888–5896. 2005. View Article : Google Scholar : PubMed/NCBI
27	Pua KH, Stiles DT, Sowa ME and Verdine GL: IMPDH2 is an intracellular target of the cyclophilin A and sanglifehrin A complex. Cell Rep. 18:432–442. 2017. View Article : Google Scholar : PubMed/NCBI
28	Guo Q, Huang Y, Xu J, Wang W, Gao J, Su Y, Gu Y and Yin X: Long non-coding RNA BANCR contributes to cervical adenocarcinoma migration by affecting epithelial-mesenchymal transition. Eur J Gynaecol Oncol. 40:408–412. 2019.
29	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
30	Gavert N and Ben-ZeEv A: Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med. 14:199–209. 2008. View Article : Google Scholar : PubMed/NCBI
31	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
32	Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
33	Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y and Johnson KR: Cadherin switching. J Cell Sci. 121((Pt 6)): 727–735. 2008. View Article : Google Scholar : PubMed/NCBI
34	Rao TP and Kühl M: An updated overview on Wnt signaling pathways: A prelude for more. Circ Res. 106:1798–1806. 2010. View Article : Google Scholar : PubMed/NCBI
35	Bienz M and Clevers H: Armadillo/beta-catenin signals in the nucleus-proof beyond a reasonable doubt. Nat Cell Biol. 5:179–182. 2003. View Article : Google Scholar : PubMed/NCBI
36	Li K, Pan W, Ma Y, Xu X, Gao Y, He Y, Wei L and Zhang J: A novel oncogene TRIM63 promotes cell proliferation and migration via activating Wnt/β-catenin signaling pathway in breast cancer. Pathol Res Pract. 215:1525732019. View Article : Google Scholar : PubMed/NCBI
37	Segditsas S and Tomlinson I: Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 25:7531–7537. 2006. View Article : Google Scholar : PubMed/NCBI
38	Yang J, Chen J, He J, Li J, Shi J, Cho WC and Liu X: Wnt signaling as potential therapeutic target in lung cancer. Expert Opin Ther Targets. 20:999–1015. 2016. View Article : Google Scholar : PubMed/NCBI
39	Puisieux A, Brabletz T and Caramel J: Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 16:488–494. 2014. View Article : Google Scholar : PubMed/NCBI
40	Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, Mathews CK, Shewach DS and Nikiforov MA: Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle. 7:2392–2400. 2008. View Article : Google Scholar : PubMed/NCBI